Chronos Archive seal

Review checklist: Yul Brynner (HR-ML020)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the stage, the biomarker sequence (therapy started only after tissue sequencing), the choice of pembrolizumab monotherapy, the immune-related adverse event monitoring, the rash evaluation at the sick visit, and the deviation recorded for the missed symptom screen at treatment start.
provenance reviewnot_startedThe recent-death rule does not apply (died 1985). Historical claims come from UPI, TIME, Cancer Today (AACR), Biography.com, and Encyclopedia.com. Birth-date conflicts from his own accounts are recorded as rejected alternatives. No statement or health fact is attributed to his relatives or colleagues; the histology, stage, biomarkers, and treatment are synthetic.
safe messaging reviewnot_startedTobacco claims are marked sensitive; his death is recorded without detail; the anti-smoking message is quoted as published.

Judgment calls (dossier editorial resolutions)

  1. Recent-death rule. Does not apply: Brynner died in 1985. The case still uses only published sources for history and attributes no statement or health fact to his relatives or colleagues. The interviewer to whom he described smoking as the cause of his cancer is not named. His spouse, company manager, and dresser in the modern episode are unnamed and say nothing.
  2. Birth date. The documented date is July 11, 1920, in Vladivostok (Biography.com), which agrees with his age of 65 at death in UPI and TIME. He gave other accounts himself: UPI reports that he said he was born on Sakhalin on July 11, 1915; a film reference gives July 12, 1915, as Taidje Kahn; TIME repeats the Sakhalin account. The case keeps July 11, 1920, at day precision and records the 1915 dates as conflicting alternatives. Citizenship details were not verified in a fetched source and are not used; the nationality is the roster's “Russian-born American.”
  3. Diagnosis and course. Sources agree that lung cancer was found in September 1983 and that the tumor could not be removed surgically (Cancer Today: “too close to his heart for surgery”). Cancer Today says a vocal-cord problem led to the diagnosis; the case models this as hoarseness from left vocal fold paralysis caused by aortopulmonary window disease, a recognized presentation, and does not model a laryngeal tumor. UPI places his September 1983 treatment in Hanover, Germany; a search result attributing treatment to Los Angeles could not be fetched and is not used. His 1983 treatment itself is not modeled. He returned to the stage and played the King until summer 1985 (UPI's “final bow” gives July 2; other accounts give June 30), less than four months before his death.
  4. Anti-smoking message. UPI (1986) reports the American Cancer Society message first aired on ABC in February 1986, about four months after his death; Cancer Today says networks ran it within days of his death. Both are recorded; neither date enters the episode. The smoking amounts differ (five packs a day at one time in UPI; two to four packs from age 12 in Cancer Today). The modern pack-year estimate (about 115) is a synthetic midpoint, and the quit year 1971 is from one source. Smoking claims are marked sensitive.
  5. Index age and dates. The modern episode presents Brynner at 63, at the documented diagnosis. The synthetic date of birth is July 11, 1963 (shift 43 years). The index visit on September 1, 2026 maps to September 1, 1983; the PET-CT and brain MRI (September 4), biopsy (September 9), consultation visit (September 15), treatment start (September 22), palliative care visit (September 29), voice injection (October 6), cycle 2 (October 13), sick visit (October 20), and preventive visit (October 27) map to the same days of 1983. Every date is in his lifetime and in the months of the documented diagnosis. Past medical history holds only the smoking history.
  6. Synthetic clinical picture. The histology (adenocarcinoma), stage (cT4 N2 M1c, IVB), bone metastases, PD-L1 70 percent, KRAS G12V and TP53 without an actionable alteration, pembrolizumab, zoledronic acid, laboratory results, and voice procedure are synthetic. Judgment calls: (1) bone metastases make first-line systemic therapy the standard, as the teaching objective requires; real 1983 records of spread were not used; (2) treatment waits for tissue sequencing even though plasma testing was negative, to teach the NCCN sequence; (3) pembrolizumab alone rather than with chemotherapy, a preferred option at his PD-L1 level, chosen with him to protect his energy and voice for work; (4) zoledronic acid is started with cycle 2 so a first-dose reaction is not confused with an early immune-related event.
  7. Sick visit. A same-day visit on October 20, 2026 for an itchy maculopapular rash three and a half weeks after the first dose: grade 1 immune-related dermatitis, with normal thyroid, liver, and kidney tests and mild eosinophilia; treated with a topical corticosteroid, an antihistamine, and emollients while pembrolizumab continues, per ASCO 2021. It interacts with his treatment and does not suggest any undocumented real illness.
  8. Focused visits. The three chronic-care follow-ups (diagnosis and staging review, treatment start, and cycle 2) are documented as focused visits on the CMID lung cancer monograph with NCCN, ASCO immune-related adverse event, ASCO palliative care, and NCCN distress guidance, each listing every item the protocol calls for at that point with its interval and status. Protocol deviation recorded instead of an invented result: the distress and symptom screen was not done at the treatment-start visit, a key transition, because the visit ran long; the palliative care team assessed him a week later, the next scores were lower, and screening moved to check-in. A divergence is recorded rather than a deviation: the CMID lists cortisol before each infusion, while ASCO 2021 checks it at baseline and for symptoms; with a normal baseline and no symptoms, it was not repeated at cycle 2.
  9. Consultation. The thoracic oncology referral and the consultation by Leah Morrow, MD (a fictional consultant), on September 15, 2026, are S. The consultant answers all six questions in line with what the record shows happened afterwards: stage IVB confirmed without biopsy of the bone lesions; therapy deferred until tissue sequencing, reported a week later; pembrolizumab started on September 22; the laboratory schedule followed before each cycle; zoledronic acid started with cycle 2 after the dental examination; palliative care two weeks after diagnosis; and voice injection and therapy before a graded return to work.
  10. Adult preventive visit. On October 27, 2026 (true frame October 27, 1983), at 63, so `preventive_adult`. Vaccines are the priority (influenza, PCV20, and recombinant zoster dose 1 given; COVID-19 and RSV due); colorectal screening and the statin decision are left due by shared decision until the first response scan; he declined PSA testing. Advance care planning names an unnamed health care agent and records his priorities (working on stage as long as he can, plain information, full cancer treatment now) and no other treatment preference.
  11. Not used. His 1983 treatment, his last months, hospital details, and any account by family members or colleagues. The roster's summary was not used as independent evidence.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-09-22
Progress note 03 (C-CDA)
Distress and symptom screening (NCCN Distress Thermometer, ESAS)Every visit; at minimum at key transitionsNot done today, at the start of treatment, a key transition: the visit ran long with treatment teaching. Deviation from the every-visit and key-transition screen. No harm resulted: the palliative care team assessed his symptoms and distress in full a week later, and the next scores were lower. Corrective action: the ESAS and distress thermometer are now completed on a tablet at check-in, before the clinician sees him

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-09-15
Progress note 02 (C-CDA)
LaboratoryBroad molecular profiling (tissue and plasma)OrderedPlasma cell-free DNA: no actionable alteration. Tissue next-generation sequencing pending; therapy waits for it
2026-09-15
Progress note 02 (C-CDA)
ReferralEarly integrated palliative careReferredFirst visit in two weeks
2026-09-15
Progress note 02 (C-CDA)
Self-managementVoice and work supportReferredInjection medialization and voice therapy arranged
2026-09-22
Progress note 03 (C-CDA)
ReferralEarly integrated palliative careReferredFirst visit next week
2026-09-22
Progress note 03 (C-CDA)
Self-managementVoice and work supportReferredInjection medialization in two weeks; voice therapy started

Evidence to check

Retrospective claims (R)

None.

Sensitive claims

ClaimGradeStatement
CLM-0004DHe smoked heavily for decades: UPI reported that at one time he smoked five packs of cigarettes a day, and Cancer Today reports two to four packs a day from the age of 12 and that he quit in 1971.
CLM-0007DHe said in an interview that he believed his cancer was directly caused by smoking, calling smoking "suicide."
CLM-0008DAfter his death the American Cancer Society released a 30-second television message taken from a January 1985 Good Morning America interview, in which he says: "Now that I'm gone, I tell you: Don't smoke, whatever you do. Just don't smoke."

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-10-13Glucose104 mg/dL (high)High
2026-10-20Eosinophils0.62 10*3/uL (high)High